Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

The FDA approved Neurocrine’s & AbbVie’s Endometriosis drug, Orilissa. Neurocrine stock met & surpassed the Prohost 2018 target

July 25, 2018 0

AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences (NBIX), announced that the United States FDA approved …

Biogen’s Exciting Q2 Results Highlighted Ionis (IONS) Too

July 24, 2018 0

The good news from Biogen’s (BIIB) Q2 exciting financial results comprised impressive news for Ionis (IONS) …

About PTC Therapeutics’ Acquisition of Agilis Biotherapeutics

July 20, 2018 0

Yesterday’s news unveiled that PTC Therapeutics (PTCT) has entered into an agreement to acquire Agilis Biotherapeutics. The …

Novartis Pleased the Market with Its Q2 Financial Results and Pleased Us with Its Great Scientific Achievements. See Also: The Role AveXis and RegenxBio are Playing Towards the Future Success of Novartis

July 19, 2018 0

Novartis’ (NVS) financials results exceeded analysts’ expectations. The firm’s research institutions’ strategy, well-designed structure, plans for …

Once again, we say, CRISPR is here to stay

July 18, 2018 0

A Miracle-Like Gene-Editing That People will Sooner or Later Recognize. The Wellcome Sanger Institute’s new findings …

$Amgen and UCB resubmit BLA to the FDA for the approval of Evenity™ to prevent or heal Osteoporosis bone fracture in post-menopausal women$

Amgen and UCB resubmit BLA to the FDA for the approval of Evenity™ to prevent or heal Osteoporosis bone fracture in post-menopausal women

July 13, 2018 0

The BLA Includes Data from More Than 11,000 Patients Amgen (AMGN) and UCB (Euronext Brussels: UCB) …

Stories about research, clinical trials results and an FDA ruling

July 9, 2018 0

The Week in Review #26 IN THE BIOTECH WORLD - RESEARCH - IMPROVING CRISPR GENE EDITING The problem …

Exelixis liver cancer results are gratifying, so do not worry if some pretend they do not like them

July 5, 2018 0

The New England Journal of Medicine (NEJM) published results from the CELESTIAL phase 3 pivotal trial …

The FDA Clears Compugen’s and Bayer’s IND Application for Their Checkpoint Inhibitor Immunotherapy Product

July 3, 2018 0

Finally, we are hearing what we were constantly expecting to hear coming out of Compugen’s (CGEN) …

Finding reasons for underperforming stocks

July 2, 2018 0

The Week in Review #25 When Stocks Plummet for No Relevant Reasons Sometimes investors need to know …

Why Vertex added over $20 to its stock price today

June 29, 2018 0

Health Canada Approves PrSYMDEKO™ For People Ages 12 and Older With Certain CFTR Gene Mutations Vertex …

The FDA approved a combination of two products. Both belong to Array Biopharma

June 28, 2018 0

The FDA approved Array BioPharma’s (ARRY) products Braftovi™ capsules in combination with Mektovi® tablets for unresectable or …

Exploring two clinical-stage firms with new, different approaches to treatments

June 27, 2018 0

SOPHIRIS BIO AND NANOBIOTIX SOPHIRIS BIO Sophiris Bio (SPHS) has a product called Topsalysin (PRX302) in …

Our outperforming firms and more

June 25, 2018 0

The Week in Review #24 Biotech Stocks’ Performances, Products on the Move and Biotech Research Biotechnology …

Incyte’s promising trial results and its plans to accelerate its future growth

June 21, 2018 0

Incyte (INCY) announced positive topline results from its pivotal Phase 2 REACH1 trial evaluating ruxolitinib (Jakafi®) …

Reasons for RegenxBio’s outperformance and some other Prohost big winners

June 20, 2018 0

On May 25, in Prohost Letter Issue #421, we wrote about RegenxBio (RGNX), which from behind …

Finally! CRISPR Therapeutics, Intellia Therapeutics, and Caribou Biosciences are granted the patent they have long been looking for